Darleukin - Philogen

Drug Profile

Darleukin - Philogen

Alternative Names: Anti-EDB-IL2 antibody conjugate; Anti-EDB-interleukin-2 antibody conjugate; Immunocytokine therapy; L19 interleukin-2 fusion-protein; L19-IL-2; L19-IL2 fusion protein

Latest Information Update: 15 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Philogen
  • Developer Bayer Schering Pharma; Maastricht Radiation Oncology; Philogen
  • Class Antineoplastics; Cytokines; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Immunostimulants; Interleukin-2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I/II Diffuse large B cell lymphoma; Pancreatic cancer
  • Phase I Head and neck cancer; Solid tumours
  • No development reported Renal cell carcinoma
  • Discontinued Atherosclerosis

Most Recent Events

  • 20 Jan 2016 Phase-I clinical trials in Head and neck cancer (Combination therapy) (Intralesional) before January 2016 (Philogen Pipeline, January 2016)
  • 25 Aug 2015 No recent reports on development identified - Phase-I/II for Renal cell carcinoma in European Union (IV)
  • 25 Aug 2015 No recent reports on development identified - Phase-II for Malignant melanoma (Monotherapy, Late-stage disease, Metastatic disease) in Italy, Austria and Germany (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top